A Prospective Cohort Study to Compare Weight Gain Across Different Biologic Therapy Classes in Patients with Moderate to Severe Inflammatory Bowel Diseases (IBD) Initiating Outpatient Biologic Therapy
Latest Information Update: 13 Jul 2020
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- 13 Jul 2020 New trial record
- 02 Jul 2020 Results published in the Digestive Diseases and Sciences Journal.